Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck KgaA Steps Aside For Bayer/Schering Merger To Move Forward

This article was originally published in The Pink Sheet Daily

Executive Summary

Bayer will buy Merck’s shares in Schering AG at €89 per share, or €3 more than the current bid.

You may also be interested in...



Bayer Schering Pharma SVP-Global Business Development And Licensing Michael Yeomans: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

Yeomans discusses how the firm’s increasing biologics capabilities fits into Bayer Schering’s business development strategy and the growing importance of Asia to the company.

Bayer Schering Pharma SVP-Global Business Development And Licensing Michael Yeomans: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

Yeomans discusses how the firm’s increasing biologics capabilities fits into Bayer Schering’s business development strategy and the growing importance of Asia to the company.

Bayer Schering Abandons Higher Dose Betaferon Following Disappointing Data

Head-to-head trial against Teva’s Copaxone in MS failed to show statistically significant superiority.

Related Content

Topics

UsernamePublicRestriction

Register

PS064324

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel